PharmaCyte Biotech rejects Iroquois Capital's consent solicitation to control board and cash reserves

PharmaCyte Biotech, Inc.

Iroquois Capital, a 7% holder, seeks to expand board from 7 to 15 and elect 8 nominees to gain control of $80M+ cash.
Company says Iroquois proposals are full of factual inaccuracies and would disenfranchise shareholders; urges ignoring consent cards.
PharmaCyte states Iroquois slate has limited biopharma experience; claims seven similar Iroquois board additions led to avg 30%+ stock decline.
Company reports ~90% of FDA clinical hold requests completed; two-phase pig study is last major item, progress could be jeopardized.
PharmaCyte engaged in settlement talks with Iroquois but they rejected; Iroquois bought shares at low price and sold immediately, per company.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.